𝔖 Bobbio Scriptorium

✦ LIBER ✦

774 Quality of life assessment and final results of a randomized Phase II study with single-agent gemcitabine and docetaxel given sequentially every 3 weeks show effective treatment in advanced NSCLC

✍ Scribed by L.R. Pilz; G. Koschel; J. Mezger; K. Schott; W. Spengler; C. Manegold

Book ID: 118620940
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 174 KB
Volume: 1
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(03)90799-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O-218 Single-agent Gemcitabine (G) and D

O-218 Single-agent Gemcitabine (G) and Docetaxel (D) given sequentially every 3 weeks in advanced NSCLC: Final results and quality of life assessment of a randomised phase II study show effective treatment

✍ Mezger, Joerg; Pilz, Lothar R.; Koschel, Gisela; Schott, Katrin; Hruska, D.; Man 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 170 KB

P-554 Randomized Phase II study of first

P-554 Randomized Phase II study of first-line docetaxel (D)/ gemcitabine (G) doublet chemotherapy versus fixed duration (3 cycles) sequential single agent chemotherapy (D then G) in Stage IIIB/IV non-small cell lung cancer (NSCLC)—Final Results. A study by the NSW and Australian Lung Cancer Trials Group

✍ Pavlakis, N.; McCowatt, S.; Lewis, C.; Marx, G.; Abell, F.; Della-Fiorentina, S. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 144 KB